Alternative splicing: an emerging topic in molecular and clinical oncology

Lancet Oncology

Volumn 8, Issue 4, 2007, Pages 349-357

  Pajares, María J ^a   Ezponda, Teresa ^a   Catena, Raúl ^a   Calvo, Alfonso ^a   Pio, Ruben ^a   Montuenga, Luis M ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BIVATUZUMAB MERTANSINE; BRCA1 PROTEIN; CISPLATIN; DACARBAZINE; FLUOROURACIL; GEMCITABINE; HERMES ANTIGEN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; IRINOTECAN; ISIS 3521; MESSENGER RNA PRECURSOR; NEUROFIBROMIN; OBLIMERSEN; PACLITAXEL; PARVOVIRUS VECTOR; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN MDM2; SMALL INTERFERING RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TENASCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; WT1 PROTEIN;

ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ATAXIA TELANGIECTASIA; BREAST CANCER; CANCER GENETICS; CANCER RESISTANCE; CARCINOGENESIS; CLINICAL TRIAL; COLON CARCINOMA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; ENHANCER REGION; EXON; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; HEMATOLOGIC MALIGNANCY; HUMAN; INTRON; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MICROARRAY ANALYSIS; NEPHROBLASTOMA; NEUROFIBROMATOSIS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; REGULATORY SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA INTERFERENCE; RNA PROCESSING; RNA SEQUENCE; RNA TRANSLATION; SILENCER GENE; TUMOR VASCULARIZATION; VIRAL GENE THERAPY;

ALTERNATIVE SPLICING; HUMANS; MODELS, GENETIC; MUTATION; NEOPLASMS; PROTEIN ISOFORMS; RNA, MESSENGER;

EID: 33947541694     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70104-3     Document Type: Review

References (75)

1. Modrek B., and Lee C. A genomic view of alternative splicing. Nat Genet 30 (2002) 13-19
2. Johnson J., Castle J., Garrett-Engele P., et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 302 (2003) 2141-2144
3. Caceres J., and Kornblihtt A. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 18 (2002) 186-193
4. Faustino N., and Cooper T. Pre-mRNA splicing and human disease. Genes Dev 17 (2003) 419-437
5. Garcia-Blanco M., Baraniak A., and Lasda E. Alternative splicing in disease and therapy. Nat Biotechnol 22 (2004) 535-546
6. Black D. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 72 (2003) 291-336
7. Cartegni L., Chew S., and Krainer A. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3 (2002) 285-298
8. Tacke R., and Manley J. Functions of SR and Tra2 proteins in pre-mRNA splicing regulation. Proc Soc Exp Biol Med 220 (1999) 59-63
9. Dreyfuss G., Matunis M., Pinol-Roma S., and Burd C. hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem 62 (1993) 289-321
10. Venables J. Unbalanced alternative splicing and its significance in cancer. Bioessays 28 (2006) 378-386
11. Pino I., Pio R., Toledo G., et al. Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer 41 (2003) 131-143
12. Hu G., Madore S., Moldover B., et al. Predicting splice variant from DNA chip expression data. Genome Res 11 (2001) 1237-1245
13. Fan W., Khalid N., Hallahan A., et al. A statistical method for predicting splice variants between two groups of samples using GeneChip expression array data. Theor Biol Med Model 3 (2006) 19
14. Clark T., Sugnet C., and Ares Jr. M. Genomewide analysis of mRNA processing in yeast using splicing-specific microarrays. Science 296 (2002) 907-910
15. Fehlbaum P., Guihal C., Bracco L., and Cochet O. A microarray configuration to quantify expression levels and relative abundance of splice variants. Nucleic Acids Res 33 (2005) e47
16. Yeakley J., Fan J., Doucet D., et al. Profiling alternative splicing on fiber-optic arrays. Nat Biotechnol 20 (2002) 353-358
17. Kapranov P., Drenkow J., Cheng J., et al. Examples of the complex architecture of the human transcriptome revealed by RACE and high-density tiling arrays. Genome Res 15 (2005) 987-997
18. Milani L., Fredriksson M., and Syvanen A. Detection of alternatively spliced transcripts in leukemia cell lines by minisequencing on microarrays. Clin Chem 52 (2006) 202-211
19. Lee C., Atanelov L., Modrek B., and Xing Y. ASAP: the Alternative Splicing Annotation Project. Nucleic Acids Res 31 (2003) 101-105
20. Kalnina Z., Zayakin P., Silina K., and Line A. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 42 (2005) 342-357
21. Venables J. Aberrant and alternative splicing in cancer. Cancer Res 64 (2004) 7647-7654
22. Schwerk C., and Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell 19 (2005) 1-13
23. Blencowe B. Alternative splicing: new insights from global analyses. Cell 126 (2006) 37-47
24. Ars E., Serra E., Garcia J., et al. Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum Mol Genet 9 (2000) 237-247
25. Teraoka S., Telatar M., Becker-Catania S., et al. Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences. Am J Hum Genet 64 (1999) 1617-1631
26. Liu H., Cartegni L., Zhang M., and Krainer A. A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet 27 (2001) 55-58
27. Singh R., and Valcarcel J. Building specificity with nonspecific RNA-binding proteins. Nat Struct Mol Biol 12 (2005) 645-653
28. Naor D., Nedvetzki S., Golan I., et al. CD44 in cancer. Crit Rev Clin Lab Sci 39 (2002) 527-579
29. Stickeler E., Kittrell F., Medina D., and Berget S. Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene 18 (1999) 3574-3582
30. Zerbe L., Pino I., Pio R., et al. Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing. Mol Carcinog 41 (2004) 187-196
31. Ghigna C., Moroni M., Porta C., et al. Altered expression of heterogenous nuclear ribonucleoproteins and SR factors in human colon adenocarcinomas. Cancer Res 58 (1998) 5818-5824
32. Chalfant C., Rathman K., Pinkerman R., et al. De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J Biol Chem 277 (2002) 12587-12595
33. Cascino I., Papoff G., De Maria R., et al. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol 156 (1996) 13-17
34. Midis G., Shen Y., and Owen-Schaub L. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 56 (1996) 3870-3874
35. Knipping E., Krammer P., Onel K., et al. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 38 (1995) 1735-1737
36. Li F., Ling X., Huang H., et al. Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene 24 (2005) 1385-1395
37. Zhu N., Gu L., Findley H., et al. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene 23 (2004) 7545-7551
38. Krieg A., Mahotka C., Krieg T., et al. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 86 (2002) 737-743
39. Vegran F., Boidot R., Oudin C., et al. Distinct expression of Survivin splice variants in breast carcinomas. Int J Oncol 27 (2005) 1151-1157
40. Steinman H., Burstein E., Lengner C., et al. An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J Biol Chem 279 (2004) 4877-4886
41. Kilian A., Bowtell D., Abud H., et al. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet 6 (1997) 2011-2019
42. Yi X., Shay J., and Wright W. Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res 29 (2001) 4818-4825
43. Gomez D., Lemarteleur T., Lacroix L., et al. Telomerase downregulation induced by the G-quadruplex ligand 12459 in A549 cells is mediated by hTERT RNA alternative splicing. Nucleic Acids Res 32 (2004) 371-379
44. Baudry D., Hamelin M., Cabanis M., et al. WT1 splicing alterations in Wilms' tumors. Clin Cancer Res 6 (2000) 3957-3965
45. Ferrara N., Gerber H., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
46. Grunstein J., Masbad J., Hickey R., et al. Isoforms of vascular endothelial growth factor act in a coordinate fashion To recruit and expand tumor vasculature. Mol Cell Biol 20 (2000) 7282-7291
47. Zhang H., Scott P., Morbidelli L., et al. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 83 (2000) 63-68
48. Woolard J., Wang W., Bevan H., et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 64 (2004) 7822-7835
49. Brinkman B. Splice variants as cancer biomarkers. Clin Biochem 37 (2004) 584-594
50. Lukas J., Gao D., Keshmeshian M., et al. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 61 (2001) 3212-3219
51. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 92 (2005) 212-216
52. Suga K., Yamamoto T., Yamada Y., et al. Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas. Oncol Rep 13 (2005) 891-897
53. Bartel F., Schulz J., Bohnke A., et al. Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. Int J Cancer 117 (2005) 469-475
54. Romani M., Tonini G., Banelli B., et al. Biological and clinical role of p73 in neuroblastoma. Cancer Lett 197 (2003) 111-117
55. Konecny G., Meng Y., Untch M., et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10 (2004) 1706-1716
56. Li H., Wang-Rodriguez J., Nair T., et al. Two-dimensional transcriptome profiling: identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens. Cancer Res 66 (2006) 4079-4088
57. Bracco L., and Kearsey J. The relevance of alternative RNA splicing to pharmacogenomics. Trends Biotechnol 21 (2003) 346-353
58. Esquela-Kerscher A., and Slack F. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6 (2006) 259-269
59. Kiermer V. Focus on RNA interference. Nat Methods 3 (2006) 669
60. Gleave M., and Monia B. Antisense therapy for cancer. Nat Rev Cancer 5 (2005) 468-479
61. Sazani P., and Kole R. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest 112 (2003) 481-486
62. Bruno I., Jin W., and Cote G. Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements. Hum Mol Genet 13 (2004) 2409-2420
63. Taylor J., Zhang Q., Wyatt J., and Dean N. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol 17 (1999) 1097-1100
64. Bartel F., Harris L., Wurl P., and Taubert H. MDM2 and its splice variant messenger RNAs: expression in tumors and down-regulation using antisense oligonucleotides. Mol Cancer Res 2 (2004) 29-35
65. Paz-Ares L., Douillard J., Koralewski P., et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 24 (2006) 1428-1434
66. Bedikian A., Millward M., Pehamberger H., et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24 (2006) 4738-4745
67. Lacerra G., Sierakowska H., Carestia C., et al. Restoration of haemoglobin. A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc Natl Acad Sci USA 97 (2000) 9591-9596
68. Alter J., Lou F., Rabinowitz A., et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12 (2006) 175-177
69. Puttaraju M., Jamison S., Mansfield S., Garcia, et al. Spliceosome-mediated RNA trans-splicing as a tool for gene therapy. Nat Biotechnol 17 (1999) 246-252
70. Lai Y., Yue Y., Liu M., et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol 23 (2005) 1435-1439
71. Colnot D., Roos J., de Bree R., et al. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 52 (2003) 576-582
72. Brack S., Silacci M., Birchler M., and Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 12 (2006) 3200-3208
73. Hasumi Y., Mizukami H., Urabe M., et al. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res 62 (2002) 2019-2023
74. Muraki M., Ohkawara B., Hosoya T., et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem 279 (2004) 24246-24254
75. Hayes G., Carrigan P., Beck A., and Miller L. Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res 66 (2006) 3819-3827